Merck CEO Says Personalized Cancer Vaccine Could Be Made Faster as Pipeline Advances
Merck Chief Executive Robert Davis told CNBC he expects the companyās experimental personalized cancer vaccine to become faster to manufacture over time, signaling a potential shift from early-stage scientific promise toward more scalable production. The comments add fresh attention to a closely watched oncology program that investors view as a possible long-term growth driver for Merck and a broader test case for the commercial viability of personalized cancer immunotherapy.
